TrialTargeted oncology2023

Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.

Christian Kollmannsberger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.